Growth Rate of Hepatocellular Carcinoma: Evaluation with Serial Computed Tomography or Magnetic Resonance Imaging
Overview
Authors
Affiliations
Objective: To evaluate the growth rate of untreated hepatocellular carcinoma (HCC) by calculating tumor volume doubling time (TVDT) on serial computed tomography (CT) or magnetic resonance imaging (MRI) and to predict TVDT based on initial tumor size.
Methods: Sixteen untreated HCCs in 11 patients with cirrhosis who underwent serial CT or MRI at our institution were retrospectively identified. Two independent readers recorded bidimensional measurements for all tumors, which were used to determine tumor volume (TV). Growth rate was expressed as TVDT. A mathematic model was used to predict TVDT based on baseline tumor size.
Results: Mean baseline and follow-up TVs were 10.5 cm3 (range: 0.7-243.6 cm3) and 22.0 cm3 (range: 2.5-870.8 cm3), respectively. Mean duration of follow-up was 176 days (range: 76-472 days). Mean TVDT was 127 days (95% confidence interval: 80, 203; range: 17.5-541.4 days). Expected TVDT could be expressed as TVDT = 114 x (baseline volume)0.14 (P < 0.002).
Conclusion: The results of this study suggest a preferred interval follow-up of approximately 4.5 months (127 days) for HCC screening. Small HCCs show a tendency toward faster growth and may require shorter follow-up to demonstrate progression.
Tumor Growth in Overdrive: Detailing an Aggressive Course of Hepatocellular Carcinoma.
Singh S, Delungahawatta T, Wolff M, Haas C Case Reports Hepatol. 2024; 2024:4950398.
PMID: 38974801 PMC: 11226333. DOI: 10.1155/2024/4950398.
Yang J, Yang Z, Zeng X, Yu S, Gao L, Jiang Y Chin Med J (Engl). 2023; 136(11):1322-1330.
PMID: 36921104 PMC: 10309520. DOI: 10.1097/CM9.0000000000002341.
CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017-Can Things Be Put Together?.
Caraiani C, Boca B, Bura V, Sparchez Z, Dong Y, Dietrich C Biology (Basel). 2021; 10(5).
PMID: 34066607 PMC: 8148521. DOI: 10.3390/biology10050412.
Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients?.
Sun X, Hu D, Zhang Y, Lyu N, Xu L, Chen Q J Hepatocell Carcinoma. 2020; 7:377-384.
PMID: 33365285 PMC: 7751727. DOI: 10.2147/JHC.S287641.
Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis.
Nathani P, Gopal P, Rich N, Yopp A, Yokoo T, John B Gut. 2020; 70(2):401-407.
PMID: 32398224 PMC: 7657990. DOI: 10.1136/gutjnl-2020-321040.